CTRI/2023/01/048668招募中3 期
A Multi-center, Randomized, Open-label, Comparative, Parallel Group study to assess the efficacy and safety of a fixed dose combination of Lupins Glycopyrronium plus Vilanterol plus Fluticasone dry powder inhaler versus fixed dose combination of Glycopyrronium plus Formoterol plus Fluticasone dry powder inhaler in patients with Chronic Obstructive Pulmonary Disease
upin Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects meeting all the following criteria will be participating in the trial:
- •1.Male or female patients, aged >=18 to <= 75 years at screening
- •2.Patients with a diagnosis of COPD (as defined by the GOLD Guidelines, 2021)
- •3.Post-bronchodilator FEV1 >=30% and <80% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 0.70
- •4.A modified Medical Research Council dyspnoea scale (mMRC) grade 2 or greater
- •5.History of exacerbations (>=2 moderate or >=1 severe exacerbation) of COPD within 12 months before screening
- •6.Subjects on inhaled corticosteroid (ICS) with or without a long-acting β2 agonist (LABA) (as a free or fixed combination), or ICS with a long- acting muscarinic antagonist (LAMA), or LABA with LAMA (as a free or fixed combination), or LAMA monotherapy as maintenance treatment for at least 1 month before screening
- •7.Current or previous cigarette/beedi smokers with a history of cigarette/beedi smoking of at least 10 pack/years. (Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening Visit)
排除标准
- •1.Patients who are currently receiving triple drug treatment with LABA+LAMA+ICS
- •2.Known respiratory disorders other than COPD including, but not limited to the following: asthma, tuberculosis, alpha-1 antitrypsin deficiency, cystic fibrosis, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease.
- •3.Evidence or history of other clinically significant cardiovascular disease or abnormality (such as, but not limited to, congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, arrhythmia, long QT syndrome, atrial fibrillation), renal, neurological, endocrine, immunological, psychiatric, hepatic, or hematological disease or abnormality which, in the opinion of the investigator, are clinically significant and would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study
- •4.Significant abnormality that suggests chest disease other than COPD, on chest X-ray or computed tomography (CT) scan taken within six months before screening. If there is no chest X-ray/CT scan is taken within six months prior to screening, a chest X-ray will be performed during screening to rule out any other significant abnormality
- •5.History of paradoxical bronchospasm, uncontrolled narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, or severe renal impairment or urinary retention or any other condition, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic or long-acting beta-agonist agent
- •6.History of allergy or hypersensitivity to any of the ingredients of study drugs or components of the delivery system
- •7.Suspected or confirmed SARS-COV2 infection at screening (prior to randomization the subjects will be tested for COVID 19 through rapid antigen test).
- •8.Hospitalization for COPD exacerbation or pneumonia within three months prior to screening. Any subject who experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded
- •9.Use of oral/parenteral corticosteroids or antibiotics for COPD exacerbation within six weeks prior to screening
- •10.Clinically significant abnormal electrocardiogram (ECG) finding at screening
- •11.Lung volume reduction surgery within 12 months prior to the initiation of the study
- •12.Requirement of long term ( > 12 hours daily) oxygen therapy
- •13.Unable to stop the following medications at the defined times prior to screening spirometry:
- •Medication Required washout period prior to screening spirometry
- •Ipratropium or 8 Hrs
- •ipratropium/salbutamol
- •combination product
- •Inhaled short acting β-agonists 6 hours
- •Oral β 2-agonists 48 hours
- •Long acting β-agonists
- •(salmeterol and formoterol)
- •or ICS/LABA combination products 48 hours
- •Xanthines 48 hours
- •Cromolyn and nedocromil inhalers 24 hours
- •Zafirlukast, montelukast, zileuton 48 hours
- •Long-acting anticholinergics
- •(Tiotropium etc.) 48 hours
- •Oral or parenteral corticosteroids 6 weeks
- •Any other investigational me
研究者
相似试验
进行中（未招募）
不适用
A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-8310). - ribadotChronic Hepatitis CClassification code 10008912EUCTR2005-005650-41-ESSESP
已完成
2 期
Clinical study on Yesaka Liquid in diabetic patientsCTRI/2019/05/019452Simandhar Herbal Pvt Ltd
已完成
3 期
A study of IN-SUPR-002 in Comparison With Fixed Dose Combination (FDC) of Fenofibrate and Rosuvastatin in Patients with Mixed DyslipidemiaCTRI/2014/02/004417Intas Pharmaceuticals Ltd240
进行中（未招募）
不适用
A clinical trial to assess changes in diagnosis of dementia after DaTSCANimaging in patients with suspected diagnosis of Dementia with LewyBodiesEUCTR2010-021474-11-DEGE Healthcare Ltd. and its Affiliates174
进行中（未招募）
不适用
A Multicentre, Randomised, Open-label, Comparative Phase IV Trial To Assess Changes in Dementia Diagnostic Category and Diagnostic Confidence After DaTSCAN Imaging in Subjects with an Uncertain Diagnosis of Dementia with Lewy Bodies (DLB)Subjects with possible Dementia with Lewy Bodies (DLB) who may or may not also fulfil the criteria for Alzheimers Disease (AD)EUCTR2010-021474-11-ATGE Healthcare Ltd. and its Affiliates